Published in Br J Cancer on September 01, 1999
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med (2009) 1.06
Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer (2008) 1.02
Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population. Am J Med Genet A (2008) 0.92
A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer (2009) 0.91
Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol (2005) 0.88
Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol (2011) 0.86
Differential gene expression in normal human mammary epithelial cells treated with malathion monitored by DNA microarrays. Environ Health Perspect (2005) 0.82
The effect of oxythioquinox exposure on normal human mammary epithelial cell gene expression: a microarray analysis study. Environ Health (2004) 0.77
Characterization of novel and uncharacterized p53 SNPs in the Chinese population--intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One (2011) 0.77
MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genet (2016) 0.76
Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response. J Nat Sci Biol Med (2012) 0.75
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology (1993) 3.76
p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995) 1.84
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer (1991) 1.29
p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res (1998) 1.13
Simple sequence repeat polymorphism within the p53 gene. Oncogene (1993) 1.08
P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis (1995) 1.06
A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol (1995) 1.04
A novel germ line p53 mutation in intron 6 in diverse childhood malignancies. Oncogene (1997) 1.02
p53 polymorphism in ovarian and bladder cancer. Lancet (1995) 1.00
Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem (1993) 0.98
Biallelic ApaI polymorphism of the human p53 gene (TP53). Nucleic Acids Res (1991) 0.93
Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol (1995) 0.90
Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat Res (1997) 0.89
An intron binding protein is required for transformation ability of p53. Nucleic Acids Res (1991) 0.88
HaeIII polymorphism in intron 1 of the human p53 gene. Hum Genet (1994) 0.86
TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer (1998) 0.85
Analysis of intron 4 of the p53 gene in human cutaneous melanoma. Gene (1996) 0.82
Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet (1994) 0.82
MAPMAKER: an interactive computer package for constructing primary genetic linkage maps of experimental and natural populations. Genomics (1987) 54.39
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Assessing the risk of breast cancer. N Engl J Med (2000) 3.72
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03
Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst (1999) 2.99
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Social comparison affects reward-related brain activity in the human ventral striatum. Science (2007) 2.87
Psoas abscess: case report and review of the literature. J Urol (1992) 2.84
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res (2000) 2.83
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol (1993) 2.79
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae. Infect Immun (2001) 2.75
Genetic risk and behavioural change. BMJ (2001) 2.64
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer (1997) 2.53
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther (2008) 2.49
Human ovarian tissue cryopreservation: quality of follicles as a criteria of effectiveness. Reprod Biomed Online (2010) 2.46
Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol (2001) 2.41
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med (2000) 2.39
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer (1996) 2.33
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet (2000) 2.31
Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods (1998) 2.31
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2008) 2.27
PET with 18fluorodeoxyglucose and hexamethylpropylene amine oxime SPECT in late whiplash syndrome. Neurology (1998) 2.17
Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science (1988) 2.15
Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet (1997) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
Single dose kinetics of mefloquine in man. Plasma levels of the unchanged drug and of one of its metabolites. Chemotherapy (1982) 2.06
Human hippocampus establishes associations in memory. Hippocampus (1997) 2.03
BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet (2014) 2.02
A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol (2001) 2.01
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Non-random association between alleles detected at D4S95 and D4S98 and the Huntington's disease gene. J Med Genet (1989) 1.95
On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet (1997) 1.94
Ethnic differences in risk perception among women at increased risk for breast cancer. Breast Cancer Res Treat (1996) 1.94
DNA screening for breast/ovarian cancer susceptibility based on linked markers. A family study. Arch Intern Med (1993) 1.91
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet (2001) 1.87
Consent to the use of stored DNA for genetics research: a survey of attitudes in the Jewish population. Am J Med Genet (2001) 1.87
p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet (1995) 1.84
Laparoscopic cholecystectomy for acute cholecystitis: prospective trial. World J Surg (1997) 1.82
Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility. Am J Med Genet (1997) 1.82
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res (2001) 1.81
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Why do some women get regular mammograms? Am J Prev Med (1991) 1.78
Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res (2000) 1.76
Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns (1997) 1.75
Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol (2002) 1.72
Is Swedish snus associated with smoking initiation or smoking cessation? Tob Control (2005) 1.72
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addict Behav (1998) 1.68
Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol (2005) 1.67
A breast-ovarian cancer susceptibility gene maps to chromosome 17q21. Am J Hum Genet (1993) 1.66
Risk communication in genetic testing for cancer susceptibility. J Natl Cancer Inst Monogr (1999) 1.66
Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy. Ann Surg (1996) 1.66
Delay of surgery in acute appendicitis. Am J Surg (1997) 1.66
Human hippocampus associates information in memory. Proc Natl Acad Sci U S A (1999) 1.62
Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium. Cancer (1996) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61